araag2/HINT huggingface dataset:
Clinical trial NCT01435044 (phase 2, status: completed)
Conditions: hepatitis c, chronic
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: sofosbuvir, gs-0938, rbv, placebo to match sofosbuvir, placebo to match gs-0938
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, CCOC1=C2N=CN([C@@H]3O[C@@H]4CO[P@@](=O)(OC(C)C)O[C@H]4[C@@]3(C)F)C2=NC(N)=N1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Chronic HCV-infection

          -  Naive to all HCV antiviral treatment

          -  Otherwise healthy patients

        Exclusion Criteria:

          -  Positive test at Screening for HBsAg, anti-HBc IgM Ab, or anti-HIV Ab

          -  History of any other clinically significant chronic liver disease

          -  Medical history which the investigator considers the patient unsuitable for the study
Clinical trial NCT00738582 (phase 2, status: completed)
Conditions: malignant pleural mesothelioma
ICD codes: C45.9, C45.0, C45.1, C45.2, C45.7
Drugs: morab-009 (amatuximab), pemetrexed, cisplatin
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Primary Inclusion Criteria:

          -  Confirmed diagnosis of malignant pleural mesothelioma (MPM) with the following
             characteristics: unresectable disease (or otherwise not a candidate for curative
             surgery); epithelial type or biphasic (mixed) type with low sarcomatous content.

          -  Measurable disease at Screening by computed tomography (CT)(or magnetic resonance
             imaging [MRI]).

          -  KPS of greater than or equal to 70% at Screening.

          -  Life expectancy of at least 3 months

        Primary Exclusion Criteria:

          -  Sarcomatous type of mesothelioma

          -  Prior systemic therapy or radiotherapy for MPM; local radiotherapy for symptom control
             (ie, non-curative intent) is permitted.

          -  Confirmed presence of CNS tumor involvement.

          -  Evidence of other active malignancy requiring treatment.
Clinical trial NCT00451555 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: enzastaurin, placebo, fulvestrant
SMILES: CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=CC=CC=N3)CC2)C2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Female participants with a histological-documented diagnosis of locally advanced or
             metastatic breast cancer. The primary or metastatic tumor must be estrogen response
             (ER) and/or parathyroid hormone receptor (PtR) positive.

        Note: Hormone receptor positivity is defined as ER or PtR greater than 10 fmol/mg by
        biochemical assay or 10% positive cells by immunohistochemistry

          -  Participants are resistant to aromatase inhibitors (AI) therapy

          -  Females with postmenopausal status

          -  Previous radiation therapy is allowed, but should have been limited

          -  Measurable or non-measurable disease

          -  Have a performance status of 0, 1, or 2 on the Eastern Cooperative Oncology Group
             (ECOG) scale

          -  Have adequate organ function

          -  Have an estimated life expectancy of at least 24 weeks

          -  Must sign an informed consent document

        Exclusion Criteria:

          -  Have had prior treatment with fulvestrant or enzastaurin

          -  Are receiving concurrent administration of any other antitumor therapy, with the
             exception of gonadotropin-releasing hormone (GnRH) antagonists.

          -  Have received treatment within the last 4 weeks with a drug that has not received
             regulatory approval for any indication at the time of study entry

          -  Have received supplemental estrogen or progesterone within 4 weeks prior to study
             entry

          -  Are hormone estrogen receptor (HER2)-positive

          -  Are unable to discontinue use of anticoagulants

          -  Have hypercalcemia

          -  Have a second primary malignancy that is clinically detectable at the time of
             consideration for study enrollment

          -  Have documented central nervous system (CNS) metastases, symptomatic pulmonary
             lymphangitis, or involvement of more than 1/3 of the liver

          -  Have a serious concomitant systemic disorder

          -  Have a serious cardiac condition

          -  Are unwilling or unable to discontinue use of carbamazepine, phenobarbital, or
             phenytoin at least 14 days prior to study therapy

          -  Are unable to swallow tablets.
Clinical trial NCT00559871 (phase 2, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: fipamezole
SMILES: CCC1(CC2=CC=C(F)C=C2C1)C1=CNC=N1
Eligibility criteria:

        Main Inclusion Criteria:

          -  Idiopathic Parkinson's disease.

          -  Levodopa/DDI associated peak-dose dyskinesia which is at least moderately disabling
             and present for ≥25% of the waking day (UPDRS part IV, items 32 and 33, each ≥ 2).

          -  Stable Parkinson's medication for at least 1 month prior to randomization.

          -  Hoehn and Yahr Stages 1 to 4 during 'Off' period.

          -  Demonstrated ability to comprehend and give informed consent.

          -  Ability to complete patient diary.

        Main Exclusion Criteria:

          -  Other clinically significant conditions apart from those typically associated with
             Parkinson's disease.

          -  Intake of medication associated with exacerbation of dyskinesia or with extrapyramidal
             side effects and tardive dyskinesia or induction of liver enzymes; neuroleptics; or
             specified drugs known to be substantially metabolized through the following cytochrome
             P450 isoenzymes: 1A2, 2B6, 2C19, 2C9, 2D6, and 2E1.

          -  Use of St. John's Wort or Ginkgo Biloba within 48 hrs prior to randomization and until
             the last treatment day with the study medication.

          -  Intake of an investigational drug within 30 days prior to initial screening.
Clinical trial NCT00636961 (phase 2, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: indacaterol 300μg, placebo
SMILES: CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female subjects,

          -  40 to 80 years of age,

          -  with a documented diagnosis of mild, moderate or severe chronic obstructive pulmonary
             disease (COPD) according to Global Initiative for Chronic Obstructive Lung Disease
             (GOLD) criteria and >20-pack year history of smoking, a post-bronchodilator 40% ≤ FEV1
             ≤ 80% of predicted normal and post-bronchodilator FEV1/FVC < 70% who have signed an
             informed consent form (ICF) prior to the initiation of any study-related procedure
             (Post bronchodilator refers to 30 minutes after the inhalation of 400 µg of
             salbutamol)

          -  Subjects who demonstrate a plethysmographic functional residual capacity >120%
             predicted normal

        Exclusion Criteria:

          -  No COPD exacerbations within 6 weeks prior to dosing,

          -  no concomitant lung disease such as asthma,

          -  no requirement for long term oxygen treatment or history of lung reduction surgery.

          -  No medical conditions that would interfere with the performance of spirometry or
             clinical exercise testing.

          -  Any other medical condition that in the opinion of the investigator may cause the
             patient to be unsuitable for completion of the study or place the patient at potential
             risk from participating in the study e.g. uncontrolled hypertension or unstable
             ischemic heart disease

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT01521663 (phase 2, status: completed)
Conditions: restless legs syndrome
ICD codes: G25.81
Drugs: ipx159, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Able to understand and willing to sign an informed consent form (ICF) and Health
             Insurance Portability and Accountability Act (HIPAA) authorization

          2. Males and females aged 18-70 with a history of primary RLS for ≥6 months prior to
             screening

          3. Symptoms of RLS by medical history on at least 15 nights during the month prior to
             Screening

          4. BMI 18.5-32

          5. Negative alcohol and drug abuse screen

          6. Negative serum pregnancy test

          7. Agrees to use a medically acceptable method of contraception throughout the study and
             for 2 months after completing the study.

          8. Able and willing to comply with the protocol, including availability for all scheduled
             clinic visits and telephone calls.

        Exclusion Criteria:

          1. Subjects who use or intend to use post screening the following medications or
             medication categories:

               -  Sedative hypnotics, trazodone

               -  Dopamine agonists, gabapentin, gabapentin enacarbil, pregabalin

               -  Narcotic analgesics, other opioids, tramadol, cyclobenzaprine

               -  Iron supplementation therapy

          2. History of HIV, hepatitis B or C

          3. Pregnant or breastfeeding.

          4. History of or clinical signs of any form of epilepsy or seizures, excluding
             fever-related seizures in childhood.

          5. History or presence of glaucoma

          6. Planning to take herbal medications (eg, hypericum perforatum [St John's Wort],
             licorice, ephedra, ginkgo, ginseng) during the study.

          7. Use of any investigational drug within the last 30 days or within a period of 5 times
             the drug's half-life, whichever is longer

          8. Subjects who, in the opinion of the Investigator, should not participate in the study
             or are not capable of following the study schedule for any reason

          9. Employees or family members of the Investigator, study site, the Sponsor, or Contract
             Research Organization (if any)
Clinical trial NCT00289640 (phase 2, status: completed)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: ipilimumab (mdx-010, bms-734016), ipilimumab, ipilimumab
SMILES: COC1=CC=CC=C1OCC(O)CO, COC1=CC=CC=C1OCC(O)CO, COC1=CC=CC=C1OCC(O)CO
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with previously treated, therapy-refractory or -intolerant, Stage III
             (unresectable) or Stage IV melanoma
Clinical trial NCT00735345 (phase 2, status: terminated)
Conditions: esophageal cancer
ICD codes: K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10
Drugs: 5-fu, cisplatin, taxotere
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Reason stopped: 
    because of safety concerns the study was terminated prematurely
  
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent

          -  histologically confirmed esophageal cancer (squamous cell carcinoma)

          -  measurable, non-metastatic disease (uT1-4)

          -  no previous cancer therapy (chemotherapy, radiotherapy or resection)

          -  life expectancy > 3 months

          -  age > 18 years

          -  WHO Status ≤ 2

          -  negative pregnancy test for women of child-bearing potential, and use of adequate
             contraception

          -  hematological status: neutrophiles ≥ 1,5x10E9/L, thrombocytes ≥ 100x10E9/L

          -  adequate renal function: serum creatinine ≤ 1,5 x ULN

          -  adequate liver function: alkaline phosphatase < 2,5 x ULN, total bilirubin < 1,5 x ULN

        Exclusion Criteria:

          -  pregnant or nursing women

          -  women of child-bearing potential without adequate contraception

          -  concomitant anti-tumoral therapy except study mandated procedures

          -  cervical esophageal cancer or diagnosis of metastases

          -  participation in other clinical trials within the last 30 days

          -  history of malignant disease within the last 5 years

          -  peripheral neuropathy (NCI CTC ≥ grade 1)

          -  concurrent active and serious non-malignant diseases: uncontrolled heart
             insufficiency, angina pectoris, hypertension or arrhythmias, liver disease,
             significant neurological or psychiatric conditions

          -  active infections
Clinical trial NCT01349231 (phase 2, status: completed)
Conditions: obsessive-compulsive disorder
ICD codes: F42.8, F42.9, F60.5
Drugs: ketamine
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          1. Adult between the ages of 18 and 65 years.

          2. Meet DSM IV criteria for obsessive-compulsive disorder by structured clinical
             interview (SCID) and have a Y-BOCS score >24.

          3. Have treatment-refractory OCD. Have Y-BOCS>24 despite two SSRI trials of adequate dose
             and duration and been offered prior CBT treatment.

          4. Stable psychiatric medications. Subjects must have had stable doses of all psychiatric
             medications for the month prior to treatment and have been on stable doses of SSRI and
             clomipramine for at least 2 months prior to study enrollment.

          5. Medically and neurologically healthy.

          6. Able to provide written informed consent according to the Yale HIC guidelines.

        Exclusion Criteria:

          1. Lifetime history of substance dependence (other than nicotine and caffeine)

          2. Suicide attempt or suicidal ideation requiring psychiatric hospitalization in the
             previous 6 months

          3. Being Pregnant

          4. Known hypersensitivity to ketamine
Clinical trial NCT01175291 (phase 2, status: withdrawn)
Conditions: metastatic colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: mk-0646, placebo
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    treatment deemed ineffective so accrual was closed
  
Eligibility criteria:

        Inclusion Criteria:

          -  Metastatic colorectal adenocarcinoma.

          -  Measurable disease by RECIST criteria.

          -  Adequate hepatic function: total bilirubin ≤2.0 x upper limits of normal (ULN);
             Aspartate Amino Transferase (AST)/Alanine Amino Transferase (ALT) ≤3.0X upper limits
             of normal (or ≤5X upper limits of normal if attributable to liver metastases).

          -  Adequate renal function: serum creatinine ≤2.0 mg/dl.

          -  Adequate bone marrow function: absolute neutrophil count ≥1,500/mm3; platelets ≥
             100,000/mm3.

          -  Prothrombin time (PT) and activated partial thromboplastin time (aPTT) levels ≤1.5
             upper limit of normal (unless patients receiving coumadin anticoagulation in which
             case a stable international normalized ratio (INR) of 2-3 is required).

          -  Age ≥ 18 years.

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.

          -  Life expectancy ≥ 12 weeks.

          -  Negative pregnancy test.

          -  Ability to sign informed consent.

        Exclusion Criteria:

          -  Prior systemic chemotherapy for metastatic colorectal cancer

          -  Prior oxaliplatin in the adjuvant setting within 12 months

          -  Uncontrolled central nervous system metastases or carcinomatous meningitis.

          -  Myocardial infarction in the past 6 months.

          -  Major surgery within 8 weeks prior to enrollment.

          -  Uncontrolled serious medical or psychiatric illness.

          -  Inadequately controlled hypertension (defined as systolic blood pressure >160mmHg, or
             diastolic blood pressure > 100mmHg).

          -  Pregnant or lactating women. Both men and women of childbearing potential must be
             advised of the importance of using effective birth control measures during the course
             of study.

          -  Prior experimental therapy targeting the IGF-1 pathway

          -  Concurrent malignancy (with the exception of squamous or basal cell skin carcinoma)

          -  Planned surgical metastasectomy

          -  Patient has known hypersensitivity to components of treatment, their analogs, or drugs
             of similar chemical or biologic composition
Clinical trial NCT01318642 (phase 2, status: terminated)
Conditions: adenocarcinoma of the pancreas, locally advanced, unresectable
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, H35.3123
Drugs: gemcitabine, amg 479, placebo
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    nct01318642: planned independent dmc interim review: ended for futility w/no safety concerns
  
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must have histologically or cytologically confirmed locally advanced
             adenocarcinoma of the pancreas that is unresectable, per institutional practice

          -  Radiologically measurable and/or non-measurable disease as defined by RECIST version
             1.1

          -  Eastern Cooperative Oncology Group (ECOG) score of 0 or 1

          -  Men or women >/= 18 years of age

          -  Adequate organ function

        Exclusion Criteria:

          -  Early (stage I) or metastatic (stage IV) disease

          -  Islet cell, acinar cell carcinoma, non-adenocarcinoma, (eg, lymphoma, sarcoma, etc),
             adenocarcinoma originating from biliary tree or cystadenocarcinoma

          -  External biliary drain

          -  Currently treated or previously treated with biologic, small molecule, immunotherapy,
             chemotherapy (ie, including gemcitabine), or other agents for pancreatic cancer

          -  Currently treated or previously treated with radiotherapy, or chemoradiotherapy for
             pancreatic cancer
Clinical trial NCT01542684 (phase 2, status: terminated)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: azacytidine, gm-csf
SMILES: NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with low- or intermediate-1-risk MDS according to the International
             Prognostic Scoring System (IPSS) classification

          2. Signed informed consent indicating that patients are aware of the investigational
             nature of this study in keeping with the policies of UT MD Anderson Cancer Center.

          3. Age >/= 18 years old.

          4. Prior therapy with growth factor support, lenalidomide, or other investigational
             agents is allowed.

          5. Previously untreated patients are eligible for this study.

        Exclusion Criteria:

          1. Any previous adverse reaction (>/= Common Terminology Criteria for Adverse Events
             (CTCAE) grade 2) to GM-CSF.

          2. Prior treatment with azacytidine or decitabine.

          3. Unresolved diarrhea >/= CTCAE grade 2.
Clinical trial NCT00337259 (phase 2, status: terminated)
Conditions: non-hodgkin's lymphoma, marginal zone lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: gemcitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    poor accrual and response less than expected on interim analysis
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed marginal zone B-cell lymphoma

          -  Performance status (ECOG) ≤3

          -  Age ≥ 18

          -  At least one or more bidimensionally measurable lesion(s):

               -  2 cm by conventional CT

               -  1 cm by spiral CT

                    -  skin lesion (photographs should be taken)

                    -  measurable lesion by physical examination

          -  Laboratory values:

               -  Cr < 2.0 mg% or Ccr > 60 ml/min

               -  Transaminase < 3 X upper normal value

               -  Bilirubin < 2 mg%

               -  ANC > 1500/ul, platelet > 75,000/ul

          -  Informed consent

          -  Ann Arbor stage III or IV

        Exclusion Criteria:

          -  Any other malignancies within the past 5 years except skin basal cell ca or CIS of
             cervix

          -  Serious comorbid diseases

          -  Pregnancy or breast feeding